Sugi Predict

Sugi Predict / Compounds / SCHEMBL544028

SCHEMBL544028

SCHEMBL544028

Cc1cccc(F)c1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.54
▸ CES1 P23141 2/20 0.54
▸ TDP1 Q9NUW8 3/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ ACHE P22303 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ ALB P02768 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA7 P43166 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ CA14 Q9ULX7 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31459315 1.00 CES2 (0.54) CES2CES1TDP1L3MBTL1ACHE
Hydrochloric Acid SCHEMBL30676276 0.98 CES2 (0.52) CES2CES1TDP1L3MBTL1ACHE
SCHEMBL20971960 0.86 CES2 (0.48) CES2CES1TDP1L3MBTL1ALB
SCHEMBL355272 0.84 TDP1 (0.61) TDP1L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL260553 0.84 CES2 (0.67) CES2CES1TDP1ALBKMT2A
SCHEMBL6359374 0.83 CES2 (0.56) CES2CES1TDP1L3MBTL1ACHE
SCHEMBL11476973 0.83 CES2 (0.54) CES2CES1TDP1L3MBTL1ACHE
SCHEMBL12160758 0.83 CES2 (0.54) CES2CES1TDP1L3MBTL1ACHE
SCHEMBL28272899 0.82 CES2 (0.48) CES2CES1TDP1L3MBTL1ACHE
Hydrochloric Acid SCHEMBL7968059 0.81 CES2 (0.64) CES2CES1TDP1ALBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 — — CN claimed
CN-106748684-A A kind of method of fluorobenzaldehyde between m-fluorotoluene continuous oxidation preparation 常州大学 2017-05-31 — — CN claimed
EP-4746972-A1 DEUTERATED PARP1 INHIBITOR COMPOUNDS Duke Street Bio Limited (GB) 2026-05-27 — — EP disclosed
CN-117402104-B Preparation method of chiral intermediate of atorvastatin CHONGQING MEDICAL UNIVERSITY (CN) 2026-05-26 — — CN disclosed
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
US-20260035354-A1 PIPERIDINEDIONE DERIVATIVES INNOCURE THERAPEUTICS, INC. (KR) 2026-02-05 — — US disclosed
EP-4673137-A1 NBD1 MODULATORS AND METHODS OF USING THE SAME Sionna Therapeutics Inc. (US) 2026-01-07 — — EP disclosed
EP-4674841-A2 PHARMACEUTICAL COMPOUND Duke Street Bio Limited (GB) 2026-01-07 — — EP disclosed
EP-4640686-A1 DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Innocure Therapeutics, Inc. (KR) 2025-10-29 — — EP disclosed
US-20250313535-A1 ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF DICE MOLECULES SV, INC. 2025-10-09 — — US disclosed
US-20030149107-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2003-08-07 — — US disclosed
CN-1430629-A Stable initiator system JOHNSON & JOHNSON VISION CARE (US) 2003-07-16 — — CN disclosed
WO-2002100341-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2002-12-19 — — WO disclosed
CN-1096292-C Method for preparing bimetallic ruthenium/tin catalyst PHODIA CHIMIE (FR) 2002-12-18 — — CN disclosed
EP-0888347-A1 PHARMACEUTICALLY USEFUL COMPOUNDS Astra Pharmaceuticals Limited (GB) 1999-01-07 — — EP disclosed
CN-1204271-A Method for preparing bimetallic ruthenium/tin catalyst PHODIA CHIMIE (FR) 1999-01-06 — — CN disclosed
WO-1997034893-A1 PHARMACEUTICALLY USEFUL COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1997-09-25 — — WO disclosed
EP-0507576-A1 Polypropylene-based resin compositions TOSOH CORPORATION (JP) 1992-10-07 — — EP disclosed
CN-1034205-A Novel quinoline and preparation method thereof and the antiseptic-germicide that contains this analog derivative DAINIPPON PHARMACEUTICAL CO (JP) 1989-07-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035354-A1 PIPERIDINEDIONE DERIVATIVES CRBN, PSMC1, PSME3 CES2 4192/4885CES1 3038/4885TDP1 4369/4885
US-20250313535-A1 ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF ITGB7, ITGB4, ITGA4 CES2 4307/4885CES1 3114/4885TDP1 4660/4885
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 CES2 1727/4885CES1 286/4885TDP1 1611/4885
US-20030149107-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B CES2 425/4885CES1 45/4885TDP1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.